Actively Recruiting
Positive Association of US-FLI With the Severity of CAD
Led by Chongqing Medical University · Updated on 2024-08-21
190
Participants Needed
1
Research Sites
147 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
As a multisystem disease, metabolic dysfunction-associated fatty liver disease (MAFLD) is closely linked to the onset and progression of coronary heart disease (CHD). Ultrasonographic fatty liver indicator (US-FLI) is a semi-quantitative tool for evaluating the degree of hepatic steatosis. Our study aims to explore the relationship between US-FLI based on MAFLD and the severity of CHD.
CONDITIONS
Official Title
Positive Association of US-FLI With the Severity of CAD
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients older than 18 years old
- Patients underwent invasive coronary angiography due to chest pain, chest tightness, or other reasons at the study hospital from August 2022 to December 2023
You will not qualify if you...
- Incomplete clinical data
- Previous coronary stent implantation
- No abdominal ultrasound examination
- Poor quality of ultrasound images
- Congenital heart disease
- Tumor
- Thyroid diseases
- Infectious diseases
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
The Second Affiliated Hospital of Chongqing Medical University
Chongqing, Chongqing Municipality, China, 400000
Actively Recruiting
Research Team
T
Tingqiu Wang
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
4
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here